Patuletin

Patuletin

SCHEMBL1144553

COc1c(O)cc2oc(-c3ccc(O)c(O)c3)c(O)c(=O)c2c1O

nearest known ligand 0.86

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 3/20 0.86
AMY1A P0DUB6 3/20 0.71
PIM1 P11309 2/20 0.71
CD38 P28907 2/20 0.71
TUBB4A P04350 4/20 0.70
TUBB P07437 4/20 0.70
TUBA3C P0DPH7 4/20 0.70
TUBA1B P68363 4/20 0.70
TUBA4A P68366 4/20 0.70
TUBB4B P68371 4/20 0.70
TUBB3 Q13509 4/20 0.70
TUBB2A Q13885 4/20 0.70
TUBB8 Q3ZCM7 4/20 0.70
TUBA3E Q6PEY2 4/20 0.70
TUBA1A Q71U36 4/20 0.70
TUBA1C Q9BQE3 4/20 0.70
TUBB6 Q9BUF5 4/20 0.70
TUBB2B Q9BVA1 4/20 0.70
TUBB1 Q9H4B7 4/20 0.70
NR0B1 P51843 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Patuletin SCHEMBL29929679 1.00 XDH (0.86) XDHAMY1APIM1CD38TUBB4A
Patuletin SCHEMBL29929193 1.00 XDH (0.86) XDHAMY1APIM1CD38TUBB4A
Axillarin SCHEMBL29929599 0.92 XDH (1.00) XDHAMY1ATUBB4ATUBBTUBA3C
Axillarin SCHEMBL1155670 0.92 XDH (1.00) XDHAMY1ATUBB4ATUBBTUBA3C
Axillarin SCHEMBL29929648 0.92 XDH (1.00) XDHAMY1ATUBB4ATUBBTUBA3C
SCHEMBL19461012 0.90 TUBB4A (0.74) XDHTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL29647956 0.90 TUBB4A (0.74) XDHTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL31058466 0.90 MKNK2 (0.86) XDHMKNK2NOX4ALOX5ABCB1
SCHEMBL29143220 0.90 MKNK2 (0.86) XDHMKNK2NOX4ALOX5ABCB1
SCHEMBL31675806 0.88 TUBB4A (0.71) XDHPIM1TUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 373 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260137745-A1 QUERCETAGETIN ENRICHED MARIGOLD EXTRACTS, COMPOSITIONS, METHODS OF PREPARATION AND USE THEREOF AVT NATURAL PRODUCTS LTD (IN) 2026-05-21 US claimed
US-12514266-B2 Composition containing quercetagetin CHENGUANG BIOTECH GROUP CO., LTD. (CN) 2026-01-06 US claimed
US-20250257032-A1 METHOD OF PREPARING HIGH PURITY LUTEIN ESTER CRYSTALS, AND APPLICATIONS THEREOF AVT NATURAL PRODUCTS LTD. (IN) 2025-08-14 US claimed
CN-120195403-A Screening method of targeted CD276 small molecule inhibitor and anti-tumor application thereof 郑州大学 2025-06-24 CN claimed
WO-2025071391-A1 LIPID-BASED TOPICAL OPHTHALMIC FORMULATION FOR ENHANCING THE EFFICIENCY OF THE PENETRATION OF THE EYEBALL BARRIER BY THE BIOACTIVES PILOCARPINE, THE COUMARIN SCOPOLETIN AND PATULETIN PRESENT IN PILOCARPUS JABORANDI EXTRACT AND USE THEREOF IN PRESERVING LENS HEALTH CENTRO DE RETINA MÉDICA Y QUIRÚRGICA, S.C. (MX) 2025-04-03 WO claimed
US-20250051551-A1 IMPROVED POLYMER COMPOSITES WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) 2025-02-13 US claimed
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 US claimed
WO-2024084504-A2 QUERCETAGETIN ENRICHED MARIGOLD EXTRACTS, COMPOSITIONS, METHODS OF PREPARATION AND USE THEREOF AVT NATURAL PRODUCTS LTD. (IN) 2024-04-25 WO claimed
US-20230119060-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE MEDIENCE CO., LTD. (KR) 2023-04-20 US claimed
US-20230122252-A1 COMPOSITION CONTAINING QUERCETAGETIN CHENGUANG BIOTECH GROUP CO., LTD. (CN) 2023-04-20 US claimed
US-20090054517-A1 Phytoestrogens As Regulators Of Hedgehog Signaling And Methods Of Their Use In Cancer Treatment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-02-26 US claimed
WO-2008131354-A2 PHYTOESTROGENS AS REGULATORS OF HEDGEHOG SIGNALING AND METHODS OF THEIR USE IN CANCER TREATMENT THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) 2008-10-30 WO claimed
CN-101119719-A The use of flavonol and flavonol glycosides for stimulating growth of renal tubular epithelial cells to secrete the kidney secreting bone growth factor MIAN LONG (US) 2008-02-06 CN claimed
CN-101091706-A Excitant of dopamine transport protein and usage HEHONG BIOTECH SHANGHAI CO LTD (CN) 2007-12-26 CN claimed
EP-1847265-A1 THE USE OF FLAVONOL AND FLAVONOL GLYCOSIDES FOR STIMULATING GROWTH OF RENAL TUBULAR EPITHELIAL CELLS TO SECRETE THE KIDNEY SECRETING BONE GROWTH FACTOR Long, Mian (US) 2007-10-24 EP claimed
CN-101019557-A Recipe and prepn of botanical composite pesticide BEIJING TIANDILUYUAN INST OF A (CN) 2007-08-22 CN claimed
CN-1742983-A Composition containing herbal medicine component for promoting absorption and production method thereof OSHIRO KIYOTOSHI (JP) 2006-03-08 CN claimed
EP-0868914-B1 USE OF A FLAVONOID-CONTAINING EXTRACT OF THE PLANT EUPHORBIA PROSTRATA IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF AN ANORECTIC OR COLONIC DISEASE PANACEA BIOTEC LTD (IN) 2002-12-18 EP claimed
US-5858371-A Pharmaceutical composition for the control and treatment of anorectal and colonic diseases PANACEA BIOTECH LIMITED (IN) 1999-01-12 US claimed
EP-0868914-A1 Pharmaceutical composition for the control and treatment of anorectal and colonic diseases PANACEA BIOTEC LIMITED (IN) 1998-10-07 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230119060-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE SLC5A2, SLC5A1, SLC5A6 XDH 2936/4885AMY1A 2463/4885PIM1 3429/4885
US-20260137745-A1 QUERCETAGETIN ENRICHED MARIGOLD EXTRACTS, COMPOSITIONS, METHODS OF PREPARATION AND USE THEREOF LIPA, LIPC, CUTA XDH 990/4885AMY1A 50/4885PIM1 3311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.